The first compact and easy-to-use microreactor device for Body-On-Chip experiments.

Project Information

B-On-Chip

Grant agreement ID: 762315

DOI

10.3030/762315

Project closed

EC signature date 23 January 2017

Start date 1 January 2017

End date 31 May 2017

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

BEONCHIP SL
Spain

Periodic Reporting for period 1 - B-On-Chip (The first compact and easy-to-use microreactor device for Body-On-Chip experiments.)

Reporting period: 2017-01-01 to 2017-05-31

Summary of the context and overall objectives of the project

BEOnChip S.L. is a leading company focused on the field of Micro-biotechnology. We count on a patent portfolio of microfluidic chips to be used as organ-on-chips that can be defined as micro-sized artificial organs with the unique ability to host different cells to mimic human-type responses to new drugs. Now, in the B-On-Chip project we seek bringing to the market the first compact, fully automated and easy-to-use device to link multiple organs-on-chip, enabling the so-called body-on-chip experiments. The use of B-On-Chip by the Pharma industry has the potential to reduce the use of laboratory animals, to accelerate drug development and to study how reactions in one organ affect another. Therefore, B-On-Chip will offer the most accurate in vitro data on new drug efficiency, security, and toxicity in a fast, automatic and reliable way.

OBJECTIVES FOR THE ACTION

F.0.1-To search for and identify potential suppliers of Microreactor technology components in EU.
F.0.2- To build up a work plan for final technology development: key milestones, tasks and risk analysis.
F.0.3-To search for and identify potential distributors in EU and define our commercialization strategy
F.0.4-To define our IP strategy and perform a patentability analysis.
F.0.5-To perform a market analysis to define the best channels for entering different geographic markets.
F.0.6- Preparation of a business plan for the next 5 years.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The work performed and the main achievements have been the following:
 We have performed an in-depth research of all companies dedicated to supply, develop and manufacture components for microfluidic technology
 We have defined a precise 2-years work plan for technology development together with a risk management plan.
 We have performed a careful analysis of distributors.
 We have performed a patentability and freedom to operate analysis.
 We have performed an exhaustive market research study.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The B-on-Chip project will not only benefit the pharmaceutical industry allowing them to reduce the long time and huge costs required for new drugs development, but it will also allow: 1) developing new, cheaper and more efficient drugs, 2) developing new biomarkers for diagnosis. All this will lead to a better quality of life for patients and life expectancy, the reduction of expenses by healthcare system.

imagen.png